Effect of perineural dexamethasone on the duration of popliteal nerve block for analgesia after ankle surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-002185-51-FI

Enrollment

Registered

2017-09-01

Start date

2017-10-18

Completion date

Unknown

Last updated

2022-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankle arthrosis, situation after ankle injury or malposition of ankle/foot, arthrodesis as a curative therapy MedDRA version: 20.0 Level: LLT Classification code 10002540 Term: Ankle arthrodesis System Organ Class: 100000021321

Interventions

Trade Name: Oradexon 5 mg/ml Product Name: Oradexon Pharmaceutical Form: Solution for solution for injection Other descriptive name: DEXAMETHASONE SODIUM PHOSPHATE Pharmaceutical form of the placebo:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient under elective ankle/food arthrodesis Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 40 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 30

Exclusion criteria

Exclusion criteria: Age under 18 years, compicated diabetes mellitus, lack of finnihs language skil and/or co-operation, chronic pain, steroid medication in regular use

Design outcomes

Primary

Measure	Time frame
Main Objective: Effect of perineural dexamethasone on the duration of popliteal nerve block after ankle/foot surgery;Secondary Objective: Prolonged postoperative pain after ankle/foot surgery;Primary end point(s): Time for first opioid request from popliteal nerve block placement;Timepoint(s) of evaluation of this end point: 48 hours after popliteal nerve block placement	—

Secondary

Measure	Time frame
Secondary end point(s): Postoperative analgesic consumption, nausea and vomiting, moobilisation, other recovery, long term quality of life and prolonged pain;Timepoint(s) of evaluation of this end point: Maximum 48 hours, quaries at 2 month, 6 month and 12 month postoperatively	—

Countries

Finland

Contacts

Public ContactMaija-Liisa Kalliomäki

Tampere University Hospital

maija-liisa.kalliomaki@pshp.fi

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026